Clinical Trials Directory

Trials / Completed

CompletedNCT02035592

The Health Effects of Blueberry Anthocyanins in Metabolic Syndrome (the CIRCLES-study)

The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
University of East Anglia · Academic / Other
Sex
All
Age
50 Years – 74 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the dose-dependent impact of 6 month freeze-dried blueberry powder intake on insulin sensitivity and resistance, cardiovascular disease risk factors, and lung and cognitive function in overweight and obese participants with metabolic syndrome. We will also examine acute post-prandial effects of blueberry intake (at baseline and at 6-months).

Conditions

Interventions

TypeNameDescription
OTHERFull dose blueberryFull dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
OTHERHalf dose blueberryHalf dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
OTHERControlControl: 26g of placebo comparator material to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.

Timeline

Start date
2014-01-01
Primary completion
2016-11-07
Completion
2016-11-07
First posted
2014-01-14
Last updated
2017-09-29

Locations

4 sites across 2 countries: United States, United Kingdom

Source: ClinicalTrials.gov record NCT02035592. Inclusion in this directory is not an endorsement.